

Neurazon INC.
Precision Health Analysis Department - Children
with Autism and Developmental Disorders
Quebec, Canada

Case no: 5430314622
First Name: Ali
Last Name: Hussein
DOB: 21.06.2021
Sex: Male

Test requested: Precision Health Analysis®

Results:

True Autism Spectrum Disorder Variants: NEGATIVE
Acquired Autism Spectrum Disorder Variants: POSITIVE
Attention-Deficit/Hyperactivity Disorder Variants: NEGATIVE
Information Processing and Brain Development Variants: NEGATIVE
White Matter Delays Variants: POSITIVE
Methylation Variants: NEGATIVE
Metabolic and Mitochondrial Function Variants: POSITIVE
Neurotransmitters, Synaptic Health, and Behavior Variants: POSITIVE
Immune System Variants: NEGATIVE
Potential Digestive System Variants: NEGATIVE
Epigenetic Regulation Variants: NEGATIVE
Potential Uncontrolled Electrical Activity: NEGATIVE

Recommended Interpretation:

- Please note any clinically relevant variants detected that are associated with the described phenotype, if present.
- Review all variants listed in the attached report, if applicable.
- We recommend reevaluating the sequence dataset every 12 months or when there are changes in the phenotype.
- Reassessment by a multidisciplinary team is advised every 3 months to monitor any observed phenotypic changes using artificial intelligence.
- A tailored intervention plan should be developed and supervised by a multidisciplinary team.


ADDITIONAL INFORMATION

This assessment was developed and validated using the AI model of NEURAZON, based on the findings outlined in the attached report. The U.S. Food and Drug Administration (FDA) has determined that clearance or approval for this method is not required; therefore, neither has been sought. All test results are thoroughly reviewed, interpreted, and reported by our team of scientific and medical experts. For full details, please refer to the attached report.

This report can not be copied or reproduced without written permission.
Reports without signature are invalid. Results are valid only for the sample analyzed.

> Contact Details

Tel.: +1 438-497 4440
customer.support@neurazon.com
www.neurazon.com



Recommended Homeopathy Plan

Step: 1st

step Name: Ali Hussein

DOB: 21.06.2021

ADDITIONAL INFORMATION

Recommendations: The provided guidance includes safe, non-drug, natural treatments intended to support the child's development. These recommendations are not a replacement for professional rehabilitation and training sessions and should always be followed under the supervision of a qualified specialist. Progress and improvement depend on the individual child, the underlying causes, and their response to the interventions, with recommendations adjusted based on regular evaluations every three months. If any signs of an allergic reaction occur, discontinue the treatment immediately and consult with a healthcare provider to modify the treatment plan accordingly.

Reevaluation: A reevaluation is necessary after the specified duration to reassess development using the AI model or as recommended by the professional team.

Next Steps: Begin the second phase of the protocol after the timeframe indicated in the treatment plan.

This assessment was developed and its performance validated using the AI model of NEURAZON, as detailed in the attached report. Based on the U.S. Food and Drug Administration (FDA) guidelines, this method does not require clearance or approval, and none has been pursued. This test is intended for clinical purposes. All results are thoroughly reviewed, interpreted, and reported by our team of scientific and medical experts. Please refer to the attached report for comprehensive details.

*This report can not be copied or reproduced without written permission.
Reports without signature are invalid. Results are valid only for the sample analyzed.*

> Contact Details

Tel.: +1 438-497 4440

customer.support@neurazon.com

www.neurazon.com



From:
Neurazon INC.
Precision Health Analysis Department - Children
with Autism and Developmental Disorders
Quebec, Canada

Order no: 5430314622
Report Type: Final report

Case no: 5430314622
First Name: ALI
Last Name: HUSSEIN
DOB: 21.06.2021
Sex: Male

Requested Test: WES (Whole Exome Sequencing)

Clinical Information/Indication: The analysis was performed according to the demand of referral center to identify variants in relevant genes associated with neurological disorders.

Result:

Main Findings:

Class 2 variant; c.1136-2A>C the SCFD2 gene was identified.
Class 3 variants; c.963T>A/p.Asp321Glu and c.5998A>G/p.Ile2000Val the CEP290 gene were identified.

Gene (Transcript)	Location	Nucleotide (protein) dbSNP	Zygosity	Variant Classification	Disease (OMIM#, Inheritance)
SCFD2 NM_152540.4	Intron 3	c.1136-2A>C	Heterozygous	Class 2	Autism Related Disorder [1] Unknown Inheritance
CEP290 NM_025114.4	Exon 12	c.963T>A p.Asp321Glu rs774072453	Heterozygous	Class 3	CEP290 Related Disorder OMIM: 610142 Autosomal Recessive
	Exon 43	c.5998A>G p.Ile2000Val rs183071230	Heterozygous	Class 3	

Details About Gene and Variants:

SCFD2: This gene is predicted to be involved in intracellular protein transport and vesicle-mediated transport. [provided by Alliance of Genome Resources, Feb 2025]

The SCFD2 variant c.1136-2A>C was detected in heterozygous state. It is classified as likely pathogenic (class 2) according to the recommendations of ACMG. This variant is associated with Autism Related Disorder [1].

[1] Pinto D. et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010 Jul 15;466(7304):368-72. doi: 10.1038/nature09146. Epub 2010 Jun 9. PMID: 20531469; PMCID: PMC3021798.

CEP290: This gene encodes a protein with 13 putative coiled-coil domains, a region with homology to SMC chromosome segregation ATPases, six KID motifs, three tropomyosin homology domains and an ATP/GTP binding site motif A. The protein is localized to the centrosome and cilia and has sites for N-glycosylation, tyrosine sulfation, phosphorylation, N-myristoylation, and amidation. Mutations in this gene have been associated with Joubert syndrome and nephronophthisis and the presence of antibodies against this protein is associated with several forms of cancer. [provided by RefSeq, Jul 2008]

The CEP290 variants c.963T>A/p.Asp321Glu and c.5998A>G/p.Ile2000Val were detected in heterozygous state. They are classified as Variant of Unknown Significance (VUS/class 3) according to the recommendations of ACMG. These variants are associated with

This report can not be copied or reproduced without written permission.
Reports without signature are invalid. Results are valid only for the sample analyzed.



From:
Neurazon INC.
Precision Health Analysis Department - Children
with Autism and Developmental Disorders
Quebec, Canada

Order no: 5430314622
Report Type: Final report

Case no: 5430314622
First Name: ALI
Last Name: HUSSEIN
DOB: 21.06.2021
Sex: Male

autosomal recessive CEP290 Related Disorder (OMIM: 610142).

Recommendations:

- Familial segregation study is recommended to reveal cis/trans phase of the variants detected in CEP290 gene.
- It is recommended to evaluate this patient's result together with clinical and laboratory findings.
- Genetic screening and clinical evaluation are recommended for family members.
- Genetic counseling is recommended.

Additional Findings:

The variants reported as additional findings refer to pathogenic changes that are not related to the referred phenotype but can cause additional phenotype thus require genetic counseling and further clinical evaluation.

ACMG Findings (ACMG 81 Genes):

According to the ACMG guidelines (Genetics in Medicine, 2023; PMID: PMID: 37347242), Class 1 or 2 incidental changes in proposed diseases and genes are reported. Variants in the BRCA1/2, MLH1, MSH2, MSH6, PMS2, TMEM127, MAX and MUTYH genes associated with adult onset diseases in children (under 15 years of age) are not reported.

Carriership Findings:

Class 1 and class 2 variants in genes selected according to OMIM phenotypes associated with severe or early-onset diseases have been reported. The variants reported as carriership findings refer to pathogenic changes that are not related to the reported phenotype and require family screening in conjunction with genetic counseling due to potential carrier risk.

Gene (Transcript)	Location	Nucleotide (protein) dbSNP	Zygosity	Variant Classification	Disease (OMIM#, Inheritance)
PAH NM_000277.3	Exon 12	c.1208C>T p.Ala403Val rs5030857	Heterozygous	Class 1	Phenylketonuria OMIM:261600 Autosomal Recessive

Method:

Whole Exome Sequencing is performed by DiagnoSeq using Twist Biosciences technology. First, approximately 36.5 Mb of Consensus Coding Sequences (CCS) (targeting > 98% of RefSeq and Gencode v28 regions derived from the human genome) are replicated from fragmented genomic DNA with the Twist Human Core Exome Plus kit. The generated library is sequenced on the Illumina Novaseq NGS platform to achieve a minimum reading depth of 20x for >98% of the targeted bases. As a result of sequencing, raw data is obtained in FASTQ and VCF formats. Whole Exome Sequencing analysis is performed on FASTQ data using the Franklin by Genoox analysis program. In addition to all disease-causing variants reported in the HGMD®, ClinVar, and CentoMD® databases as well as all variants with a Minor Allele Frequency (MAF) of less than 1% in the gnomAD database are considered. The research for related variables has focused on coding exons and surrounding +/- 20 intronic bases. All potential inheritance patterns are covered. In addition, the family history and clinical information provided are used to evaluate pathogenicity and variables defined by their cause

This report can not be copied or reproduced without written permission.
Reports without signature are invalid. Results are valid only for the sample analyzed.



From:
Neurazon INC.
Precision Health Analysis Department - Children
with Autism and Developmental Disorders
Quebec, Canada

Order no: 5430314622
Report Type: Final report

Case no: 5430314622
First Name: ALI
Last Name: HUSSEIN
DOB: 21.06.2021
Sex: Male

of disease and are classified in Class 1 - 5 scoring **. All variables related to the patient's phenotype are reported, except for benign or possible benign variants. Low-quality single nucleotide variants and all related deletion/insertion variants are validated by Sanger sequencing.

Analysis Statistics:

Average Depth	150
Variant Quality	99%

Method Limitations:

Polymorphisms in primary binding and regions, CNV duplications and somatic microsatellite variations, tissue mosaic, high GC nucleotide content can lead to false positive / negative results. False positive findings may occur due to large deletion / point mutation combined heterozygosity. Variants in transcripts other than canonical transcripts cannot be eliminated, and differences may occur between exon numbers and mutation positions depending on the transcript type sequenced. This method does not show heterozygous deletions and duplications in rare exons and nucleotide changes in other regions of the gene.

Variants with the allele fraction below 30% for regions with a sensitivity of this test of 50X read count are not reported. Additionally, due to technology limitations, some regions may be either not covered or poorly covered. Variables in these regions cannot be reliably detected. Areas with extremely low readings are considered artifacts as a result of validation studies, and they were not taken into account during the analysis. Copy number changes, inversions, translocations and repeat sequence increases cannot be detected by the NGS method.

The genetic results are interpreted in the context of the provided clinical findings, family history, and other laboratory data. Only variants in genes potentially related to the proband's medical condition are reported. Misinterpretation of results may occur if the provided information is inaccurate and/or incomplete. If the obtained genetic results do not concur with the clinical findings, additional testing should be considered.

**Variant Classification (According to American College of Medical Genetics ACMG)

- Class 1 – Pathogenic
- Class 2 – Likely pathogenic
- Class 3 – Variant of Unknown Significance -VUS
- Class 4 – Likely benign
- Class 5 – Benign

This report can not be copied or reproduced without written permission.
Reports without signature are invalid. Results are valid only for the sample analyzed.

> Contact Details

Tel.: +1 438-497 4440
customer.support@neurazon.com
www.neurazon.com

From:
Neurazon INC.
Precision Health Analysis Department - Children
with Autism and Developmental Disorders
Quebec, Canada

Order no: 5430314622
Report Type: Final report



Case no: 5430314622
First Name: ALI
Last Name: HUSSEIN
DOB: 21.06.2021
Sex: Male

This test was analyzed by Neurazon, Canada.

Digitally Approved by:

Dr. Carmel Katz

Lead Scientist and Geneticist

Lead Bioinformatics Specialist

At Neurazon

This report can not be copied or reproduced without written permission.
Reports without signature are invalid. Results are valid only for the sample analyzed.